Medicines Management Optimisation Achieving your 5 a day post-mi Medication WORKSHOP

Size: px
Start display at page:

Download "Medicines Management Optimisation Achieving your 5 a day post-mi Medication WORKSHOP"

Transcription

1 Medicines Management Optimisation Achieving your 5 a day post-mi Medication WORKSHOP

2 What is Medicines Optimisation? the safe and effective use of medicines to enable the best possible outcomes NICE ng

3 What do BACPR S&CC say? Cardioprotective Medication Current use of cardioprotective medication should be assessed (inc adherence) with the aim of ensuring uptitration of medication during the programme so that evidence-based dosages are achieved. Patients beliefs about medication should also be assessed as this affects adherence to drug regimens Key drugs: antiplatelets, lipid-lowering, betablockers, ACE-I/AIIRA, calcium channel blockers, anticoagulants, diuretics

4 What do CC for HBC&E say? Recognise opportunities and barriers to implementing interventions Agree goals for the intervention Implement behaviour change in a manner consistent with its underlying philosophy Make and review action plans based on identified goals Carry out health behaviour problem solving End the intervention in a planned manner and to plan for long term maintenance of the new health behaviours

5 What about non-medical prescribing? Aims: Medicine access patient choice increased more efficient and quicker Improve access to advice & services; Good use of appropriately skilled & placed healthcare workforce Includes allowing doctors to make best use of their expertise Contribute to an integrated seamless healthcare system; Increase capacity to meet the increased demand for the provision of new and existing NHS services; Improve patient care without compromising patient safety

6 Medicines Optimisation achieving 5-a-day as part of cardiac rehabilitation 0. General post-mi 1. Single / dual antiplatelet therapy 2. ACE-I / AIIRA 3. Statin 4. Betablocker 5. GTN 5. PPI

7

8 0. General post-mi medication

9 0. General post-mi medication Reduced morbidity & mortality Reduce progression of disease (CHD. ACS. HF) Keenness to follow instructions High contact with CR for modifications, answers, info Address misconceptions Fit with lifestyle Instil ownership History & Examination Usual effects & s.effects of medications vs those of post-mi Effective system for your team & area Negotiation, communication, listening, pt-centred skills Guidelines Newness forgetting medication, lack of fit Wellness need not felt Side-effects of medication vs s.effects of post-mi Ownership. Whose job is it? Time for assessment, review, up-titration, follow-up Access to notes System safe, effective, individualised, aspirational CR play its part in the bigger picture: pt. relative. GP. PN. Cardiologist. Pharmacist. Daily News. Others Role of self Education & information opportunities

10 1. Anti-platelet: single / dual

11 1. Anti-platelet: single / dual Reduce platelet aggregation DAPT for time-limited period Bruising Bleeding Upper GI symptoms BD forgetfulness Misunderstanding of need for both synergistic effect Past gastric ulceration/issue, bleeding hx, age, anaemia. AF Surgery Anticoagulant Abdominal tenderness Aspirin: with or without water; with food Communicate length of therapy Doors and windows - DAPT Guidelines?

12 2. ACE-I / AIIRB

13 2. ACE-I / AIIRB Prevent HF. Reduced morbidity & mortality Re-introduction post revascularisation Up-titration. Down-titration Monitoring Sx, U&E, BP Symptomatic low BP Cough Angioedema. Renal failure. Bilateral RAS Ownership over titrations Past intolerance cough, angioedema, bilateral RAS Renal function Diuretics. Potassium supplementation Hypertension. HF U&E 7 days post up-titration Guidelines? Planned what to do if; monitoring; holidays Shared care GP, PN, Cardiologist, CR team nonprescribers, PATIENT Communication

14 3. Statin

15 3. Statin Reduce mortality and morbidity Improve the numbers lower LDL & cholesterol (when to test?) Reduce vascular inflammation, stabilise plaque Up-titrate. Down-titrate. Switch Past intolerance really? Alcohol excess Liver function test Familial hyperlipidaemia. Simon Broom criteria Lipid levels Guidelines? Simvastatin circadian rhythm forgetfulness Myopathy vs new exercise effect Keeping up with the latest news My cholesterol is normal Establishing on suitable, effective drug & dose Cost? Monitoring muscular aches CK after 2 day exercise-free symptomic only With exercise (HDL), weight loss, healthy eating Familial hypercholesterolaema nurse

16 4. Betablocker

17 4. Betablocker Up to 1 year post MI Reduce symptoms in HF Improve survival Up-titration. Down-titration. De-prescribing Timing Wheeze. Tiredness. Cold peripheries. ED. Mood Bradycardia. Heart block. Asthma 5 day dip post up-titration Reduced hypoglycaemia warning Chest conditions. Intolerance. Pulmonary oedema. Unstable HF Hypertension. Angina Guidelines? Planned what to do if; monitoring; holidays Shared care GP, PN, Cardiologist, CR team nonprescribers, PATIENT Communication

18 5. Nitrolingual spray

19 5. Nitrolingual spray Peripheral vasodilatation Increase confidence Reduce fear Reduce unnecessary re-admission Prophylaxis when pattern established Join with what to do if advice Past use. Associations of past use at MI ED & use of PDE5 inhibitors Trial in your clinic? Guidelines? Headaches. Hypotension Dyspepsia vs angina vs MSK vs anxiety Fear of use inevitable admission fear Embarrassment. Family concern Taste associated with effectiveness PDE5 inhibitors Avoid scare-induction Panic! I ve forgotten my spray Review if new or increased need for spray

20 5. PPI

21 5. PPI Prophylaxis in view if DAPT plus Reduce unnecessary re-admissions with CP Encourage best time of day empty stomach Appropriate referral for review Up-titration. Down-titration. De-prescribing Weight loss. Healthy eating. Alcohol & nicotine reduction or cessation Past tolerance and intolerance Chest and abdo exam & palpation Anaemia Guidelines? Gastric upset try another Not all fit with Clopidogrel Head and Shoulders effect Systemic effect of Aspirin & DAPT Start as in-pt CR review & alter or refer GP Information

22 Considerations for achieving 5 a day My role in medication optimisation As non-medical prescriber in CR As non-prescriber in CR Systems in place or not in place How I fit into the bigger team with patient, family, community pharmacist, GP, practice nurse, cardiologist; working together How can I and my team alter my / our / the system so it fits? A good start Improving my/our role with one medication Use resources team, guidelines made easy, web, forums, associations Audit results & share to improve care; NMC revalidation

23

24 go forth & optimise Any questions or comments?

CARDIAC REHABILITATION PROGRAMME:- MEDICATION

CARDIAC REHABILITATION PROGRAMME:- MEDICATION CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1

More information

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice. Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to

More information

NES Asthma Hospital Medication Care Plan 7

NES Asthma Hospital Medication Care Plan 7 NES Asthma Hospital Medication Care Plan 7 PATIENT DETAILS Name Liz Duncan Address Consultant Gender Female Weight 60kg Height 1.6m General Practitioner Dr Jones Community Pharmacist Date of Birth (Age)

More information

Ischaemic Heart Disease

Ischaemic Heart Disease Ischaemic Heart Disease Katherine Rothwell Case 1 65 yr old female PMHx : Eczema, is a smoker 20/day Comes to see you complaining of central chest pain Present past few months. Comes on when gardening

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010 Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number

More information

Volume 2; Number 11 July 2008

Volume 2; Number 11 July 2008 Volume 2; Number 11 July 2008 CONTENTS Page 1 NICE Clinical Guideline 67: Lipid Modification (May 2008) Page 7 NICE Technology Appraisal 132: Ezetimibe for the treatment of primary (heterozygous familial

More information

Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease

Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines 1 This guideline is intended to assist rational and cost-effective prescribing of lipid regulating medications across both primary and

More information

Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol)

Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol) CLINICAL GUIDELINE Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol) A guideline is intended to assist healthcare professionals in the choice of disease-specific

More information

Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)

Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update) Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update) NICE guideline Apendix C The algorithms Draft for consultation, January 2010 Chronic

More information

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured. Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.

More information

Cardiovascular risk reduction in diabetes Lipids (NICE CG181)

Cardiovascular risk reduction in diabetes Lipids (NICE CG181) Cardiovascular risk reduction in diabetes Lipids (NICE CG181) Primary Prevention T1DM Offer Atorvastatin 20mg if >40 years old Diabetes duration >10 years Established nephropathy Other CVS risk factors

More information

CONCISE GUIDE National Clinical Guidelines for Stroke 2nd Edition

CONCISE GUIDE National Clinical Guidelines for Stroke 2nd Edition CONCISE GUIDE 2004 National for Stroke 2nd Edition This concise guide summarises the recommendations, graded according to the evidence, from the National 2nd edition. As critical aspects of care are not

More information

PREVENTIVE AND REHABILITATIVE MANAGEMENT OF ACUTE CORONARY SYNDROMES (NSTEMI, STEMI, PCI)

PREVENTIVE AND REHABILITATIVE MANAGEMENT OF ACUTE CORONARY SYNDROMES (NSTEMI, STEMI, PCI) PREVENTIVE AND REHABILITATIVE MANAGEMENT OF ACUTE CORONARY SYNDROMES (NSTEMI, STEMI, PCI) Dato Dr. Balachandran Kandasamy Institut Jantung Negara 12 th November 2016 KEY MESSAGES 1. Initiate a long-term

More information

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke

More information

CORONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW

CORONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW CONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN CONARY ARTERY DISEASE (CAD) MEASURES GROUP: #6. Coronary Artery Disease (CAD): Antiplatelet

More information

NICE QIPP about Lipitor. Robert Trotter. Clinical Effectiveness Consultant

NICE QIPP about Lipitor. Robert Trotter. Clinical Effectiveness Consultant NICE QIPP about Lipitor Robert Trotter Clinical Effectiveness Consultant LIP2894c Date of preparation: April 2009 Prescribing information for atorvastatin is available on the last slide Roadmap Background

More information

Medications. Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy.

Medications. Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy. Medications Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy. What do I need to know about medications after my heart attack? When you

More information

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.

More information

Nurse Prescribing in Cardiology. Jan Keenan Consultant Nurse; NMP Lead

Nurse Prescribing in Cardiology. Jan Keenan Consultant Nurse; NMP Lead Nurse Prescribing in Cardiology Jan Keenan Consultant Nurse; NMP Lead Jan.keenan@ouh.nhs.uk Objectives Nurse prescribing for cardiology: where are we now? What are nurses prescribing in cardiology? The

More information

Practice-Level Executive Summary Report

Practice-Level Executive Summary Report PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular

More information

Indigestion (dyspepsia)

Indigestion (dyspepsia) Commissioning pathways Indigestion (dyspepsia) Supplementary information to be read in conjunction with the pathway Reference Supplementary Information 1.1 Symptom Description Annual incidence 40%. Prevalence

More information

1/3/2008. Karen Burke Priscilla LeMone Elaine Mohn-Brown. Medical-Surgical Nursing Care, 2e Karen Burke, Priscilla LeMone, and Elaine Mohn-Brown

1/3/2008. Karen Burke Priscilla LeMone Elaine Mohn-Brown. Medical-Surgical Nursing Care, 2e Karen Burke, Priscilla LeMone, and Elaine Mohn-Brown Medical-Surgical Nursing Care Second Edition Karen Burke Priscilla LeMone Elaine Mohn-Brown Chapter 26 Caring for Clients with Coronary Heart Disease and Dysrhythmias Coronary Heart Disease (CHD) Leading

More information

Rapid access chest pain clinic (RACPC)

Rapid access chest pain clinic (RACPC) Rapid access chest pain clinic (RACPC) Context Coronary heart disease (CHD) remains the common cause of death and premture death in the UK with 15% of men and 7% of women dying from the disease. UK death

More information

1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare?

1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare? 1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare? Dr Nerys Davies, GPST Ms B. Davies, Specialist Nurse (Heart Failure) Dr J. Taylor, Consultant Cardiologist

More information

Lipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention)

Lipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention) Lipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention) Policy Statement: October 2010 This policy defines the decision made by NHS Wirral following an evidence review

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:

More information

Clinical guideline Published: 23 July 2011 nice.org.uk/guidance/cg126

Clinical guideline Published: 23 July 2011 nice.org.uk/guidance/cg126 Stable angina: management Clinical guideline Published: 23 July 2011 nice.org.uk/guidance/cg126 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

New indicators to be added to the NICE menu for the QOF and amendments to existing indicators

New indicators to be added to the NICE menu for the QOF and amendments to existing indicators New indicators to be added to the for the QOF and amendments to existing indicators 1 st September 2015 Version 1.1 This document was originally published on 3 rd August 2015, it has since been updated.

More information

What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital

What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital What is a myocardial infarction? THEY AINT WHAT THEY USED TO BE Case

More information

QOF Indicator DM013:

QOF Indicator DM013: QOF Indicator DM013: The percentage of patients with diabetes, on the register, who have a record of a dietary review by a suitably competent professional in the preceding 12 months Note: the bold signposts

More information

APPENDIX 2F Management of Cholesterol

APPENDIX 2F Management of Cholesterol Patients with established CVD: Coronary heart disease Cerebrovascular disease Peripheral vascular disease APPEDIX 2F Management of Cholesterol Patients at high risk of cardiovascular events: Chronic kidney

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:

More information

Inverclyde CHP Protected Learning Event- Heart Failure

Inverclyde CHP Protected Learning Event- Heart Failure Inverclyde CHP Protected Learning Event- Heart Failure 14:00 14:05 14:05 14:20 14:20 14:30 14:30 15:10 15:10 15:30 15:30 15:50 15:50 16:05 16:05 16:35 Welcome & Introduction Paul Forsyth (HF Pharmacist)

More information

Advanced Heart Failure Management. Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary

Advanced Heart Failure Management. Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary Advanced Heart Failure Management Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary Grading of heart failure Mr WY age 73 3/12 dyspnoea, fatigue and some ankle oedema PMH: hypertension

More information

Commissioning for value focus pack

Commissioning for value focus pack Commissioning for value focus pack Clinical commissioning group: NHS MILTON KEYNES CCG Focus area: Cardiovascular disease (CVD) pathway Version 2 June 2014 Contents 1. Background and context About the

More information

Acute Coronary Syndromes: Challenges to Management. Claire Williams November 2017

Acute Coronary Syndromes: Challenges to Management. Claire Williams November 2017 Acute Coronary Syndromes: Challenges to Management Claire Williams November 2017 Challenge 1: Diagnosis Chest pain >20 minutes ECG Challenge 1: Diagnosis Treat as STEMI Chest pain >20 minutes ECG STEMI

More information

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015 Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have

More information

CV Update Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet 27/01/09

CV Update Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet 27/01/09 CV Update Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet 27/01/09 Dr Ameet Bakhai, FRCP Cardiologist, Clinical Trials, Health Economics Barnet & Chase Farm NHS Trust Royal Free

More information

Review guidance for patients on long-term amiodarone treatment

Review guidance for patients on long-term amiodarone treatment Review guidance for patients on long-term amiodarone treatment This review guidance document has been produced in response to: 1. Current supply shortages of branded and generic versions of 100mg and 200mg

More information

Atrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency

Atrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency Atrial Fibrillation A guide for Southwark General Practice Key Messages 1. Routinely offer pulse checks to patients at high risk of AF 2. Use the CHA 2 DS 2 VASc score to identify patients for anticoagulation

More information

Flolan. Potent pulmonary and systemic vasodilator Three major potential pharmacologic actions

Flolan. Potent pulmonary and systemic vasodilator Three major potential pharmacologic actions 1995 FDA approved for PAH - NYHA functional class III/IV 2000 - FDA for SPH r/t scleroderma and related disorders 2000 Medicare expanded coverage: cardiac d/o, portal htn, SPH r/t congenital disorders

More information

Chest Pain. Dr Robert Huggett Consultant Cardiologist

Chest Pain. Dr Robert Huggett Consultant Cardiologist Chest Pain Dr Robert Huggett Consultant Cardiologist Outline Diagnosis of cardiac chest pain 2016 NICE update on stable chest pain Assessment of unstable chest pain/acs and MI definition Scope of the

More information

Long-Term Management Of the ACS Patient: State-of-the-Art. Kim Newlin, CNS, NP-C, FPCNA Sutter Roseville Medical Center Roseville, CA

Long-Term Management Of the ACS Patient: State-of-the-Art. Kim Newlin, CNS, NP-C, FPCNA Sutter Roseville Medical Center Roseville, CA Long-Term Management Of the ACS Patient: State-of-the-Art Kim Newlin, CNS, NP-C, FPCNA Sutter Roseville Medical Center Roseville, CA Disclosures I have no disclosures. Case Study 45 y/o male admitted to

More information

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Preventive Cardiology Scientific evidence

Preventive Cardiology Scientific evidence Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention

More information

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

Long-Term Complications of Diabetes Mellitus Macrovascular Complication Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent

More information

Proof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease. Produced on behalf of NHS Wales and Welsh Government

Proof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease. Produced on behalf of NHS Wales and Welsh Government Proof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease Produced on behalf of NHS Wales and Welsh Government April 2018 Table of Contents Introduction... 3 Variation in health services...

More information

Case study Chest Pain treating angina without a bypass or stent

Case study Chest Pain treating angina without a bypass or stent Case study Chest Pain treating angina without a bypass or stent Dr Clare Hawley Associate Specialist Cardiology Chesterfield Royal Hospital GPwSI for Angina Management Programme Hon Lecturer Cardiology

More information

2010 ACLS Guidelines. Primary goals of therapy for patients

2010 ACLS Guidelines. Primary goals of therapy for patients 2010 ACLS Guidelines Part 10: Acute Coronary Syndrome Present : 內科 R1 鍾伯欣 Supervisor: F1 吳亮廷 991110 Primary goals of therapy for patients of ACS Reduce the amount of myocardial necrosis that occurs in

More information

Primary Prevention of Stroke

Primary Prevention of Stroke Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for

More information

Steps Against Recurrent Stroke (STARS)

Steps Against Recurrent Stroke (STARS) Steps Against Recurrent Stroke (STARS) Take steps against recurrent stroke by making the necessary changes in your life. Your Guide to Ischemic What happened to me? You had a stroke. The stroke you had

More information

Medicine Dr. Omed Lecture 2 Stable and Unstable Angina

Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Risk stratification in stable angina. High Risk; *post infarct angina, *poor effort tolerance, *ischemia at low workload, *left main or three vessel

More information

Heart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF

Heart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange

More information

Heart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for

Heart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange

More information

MPharmProgramme. Hypertension (HTN)

MPharmProgramme. Hypertension (HTN) MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two

More information

Reducing risk in heart disease

Reducing risk in heart disease Reducing risk in heart disease An expert guide to clinical practice for secondary prevention of coronary heart disease Prof Patricia Davidson (chair) Prof Nigel Stocks Dr Anu Aggarwal Ms Jill Waddell Ms

More information

MRCP(UK) PACES. INFORMATION FOR THE CANDIDATE Training Scenario N 001 SAMPLE HOST CENTRE Station 5: BRIEF CLINICAL CONSULTATION

MRCP(UK) PACES. INFORMATION FOR THE CANDIDATE Training Scenario N 001 SAMPLE HOST CENTRE Station 5: BRIEF CLINICAL CONSULTATION INFORMATION FOR THE CANDIDATE MRCP(UK) PACES Station 5: BRIEF CLINICAL CONSULTATION Patient details: Mrs XX aged 45. Your role: You are the doctor in the medical admissions unit. You have 10 minutes with

More information

Chapter 2 - Cardiovascular System. Primary Care Prescribing Formulary - Preferred Drug Choices

Chapter 2 - Cardiovascular System. Primary Care Prescribing Formulary - Preferred Drug Choices Chapter 2 - Cardiovascular System Primary Care Prescribing Formulary - Preferred Drug Choices Drug group Drug choice Comments/notes Cardiac glycosides Thiazide diuretics Loop diuretics Aldosterone antagonist

More information

Guidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee

Guidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee Guidelines for the Management of Dyspepsia and GORD Document type: Version: 3.0 Author (name): Author (designation): Validated by Prescribing Dr. G. Lipscomb Date validated October 2015 Ratified by: Date

More information

Belinda Green, Cardiologist, SDHB, 2016

Belinda Green, Cardiologist, SDHB, 2016 Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens

More information

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME. Indicator Assessment Report

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME. Indicator Assessment Report NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Output: Advice for NHS England Assessment Report Date of QOF Advisory Committee meeting:

More information

Repeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group

Repeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group Repeat ischaemic heart disease audit of primary care patients (2002-2003): Comparisons by age, sex and ethnic group Baseline-repeat ischaemic heart disease audit of primary care patients: a comparison

More information

This information explains the advice about the care and treatment of people with stable angina that is set out in NICE clinical guideline 126.

This information explains the advice about the care and treatment of people with stable angina that is set out in NICE clinical guideline 126. Information for the public Published: 1 July 2011 nice.org.uk About this information NICE clinical guidelines advise the NHS on caring for people with specific conditions or diseases and the treatments

More information

ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour

ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical

More information

Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia

Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention

More information

5.2 Key priorities for implementation

5.2 Key priorities for implementation 5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail

More information

1 a) Please confirm or deny whether your Trust has admitted patients for acute myocardial infarction in 2008/09, 2009/10 or 2010/11

1 a) Please confirm or deny whether your Trust has admitted patients for acute myocardial infarction in 2008/09, 2009/10 or 2010/11 May 2011 1 a) Please confirm or deny whether your Trust has admitted patients for acute myocardial infarction in 2008/09, 2009/10 or 2010/11 Yes b) If confirmed please provide details on the number of

More information

Identification and management of familial hypercholesterolaemia (FH) - An overview

Identification and management of familial hypercholesterolaemia (FH) - An overview Identification and management of familial hypercholesterolaemia (FH) - An overview National Collaborating Centre for Primary Care and Royal College of General Practitioners NICE Guideline CG 71 (August

More information

Cardiology. Self Learning Package. Module 5: Pharmacology: Treatment of Acute Coronary. Prevention

Cardiology. Self Learning Package. Module 5: Pharmacology: Treatment of Acute Coronary. Prevention Cardiology Self Learning Package Module 5: Pharmacology: Treatment of Acute Coronary Syndromes, Module 5: Pharmacology: Hyperlipidaemia, Treatment of Acute Coronary Hypertension, Symdrome, Hyperlipidaemia,

More information

Frimley Health Area Prescribing Committee

Frimley Health Area Prescribing Committee Frimley Health Area Prescribing Committee Frimley Health NHS Foundation Trust North East Hampshire and Farnham CCG East Berkshire CCG Surrey Heath CCG Buckinghamshire CCG SHARED CARE Guideline Amber Traffic

More information

Coronary Artery Disease

Coronary Artery Disease Coronary Artery Disease This information is at http://www.nhlbi.nih.gov/health/dci/diseases/cad/cad_all.html and is provided by the NHLBI, one of the Institutes of the National Institutes of Health. To

More information

Cardiac Rehabilitation after Primary Coronary Intervention CONTRA

Cardiac Rehabilitation after Primary Coronary Intervention CONTRA DEBATE SESSION Is there a role for cardiac rehabilitation in the modern era of Percutaneous coronary intervention and coronary artery bypass grafting? Cardiac Rehabilitation after Primary Coronary Intervention

More information

Overview. NOT A REPETION OF LOCAL GUIDELINE Dr Diviash Thakrar

Overview. NOT A REPETION OF LOCAL GUIDELINE Dr Diviash Thakrar Overview 1. Why hypertension is important? 2. What are basic principles in treatment? 3. Different ways of measuring 4. Hypercholesterolemia NOT A REPETION OF LOCAL GUIDELINE CVD risk factors? Non modifiable

More information

Dr Joan Leighton. Professor Gerry Devlin. 14:00-14:55 WS #106: Whats Topical in Cardiology 15:05-16:00 WS #116: Whats Topical in Cardiology (Repeated)

Dr Joan Leighton. Professor Gerry Devlin. 14:00-14:55 WS #106: Whats Topical in Cardiology 15:05-16:00 WS #116: Whats Topical in Cardiology (Repeated) Professor Gerry Devlin Clinical Cardiologist and Interventional Cardiologist NZ Heart Foundation Hamilton Dr Joan Leighton General Practitioner Heart Foundation Christchurch 14:00-14:55 WS #106: Whats

More information

Sheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017)

Sheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Sheffield guidelines f the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Approved by Sheffield Area Prescribing Committee and Sheffield Teaching Hospitals

More information

What s new in Cardiovascular medicine? Dr Stephen Dorman Consultant Cardiologist, Morriston Cardiac Centre Mid & West Cardiac Network Lead

What s new in Cardiovascular medicine? Dr Stephen Dorman Consultant Cardiologist, Morriston Cardiac Centre Mid & West Cardiac Network Lead What s new in Cardiovascular medicine? Dr Stephen Dorman Consultant Cardiologist, Morriston Cardiac Centre Mid & West Cardiac Network Lead A year in review... Primary & sceondary Prevention IHD & Coronary

More information

Primary Prevention Patients aged 85yrs and over

Primary Prevention Patients aged 85yrs and over Rotherham Guideline for the management of Non-Familial Hypercholesterolaemia Type 1 Diabetes Offer lifestyle advice Over 40yrs of age? Diabetic for more than 10 years? Established nephropathy? Other CVD

More information

MyAction Couple: Primary Prevention Case Study. Teresa Mackay, Rhian Houghton, Tim Grove

MyAction Couple: Primary Prevention Case Study. Teresa Mackay, Rhian Houghton, Tim Grove MyAction Couple: Primary Prevention Case Study Teresa Mackay, Rhian Houghton, Tim Grove Reason for Referral and Patient Demographics Referral Mr Smith Referred by GP High CVD 34.5% QRISK Hypertension (155/92)

More information

Teresa Neal. Pippa Travers-Mason. Aboriginal Health Worker. Consultant clinical pharmacist MPH, Med, BPharm AACPA

Teresa Neal. Pippa Travers-Mason. Aboriginal Health Worker. Consultant clinical pharmacist MPH, Med, BPharm AACPA Teresa Neal Aboriginal Health Worker Pippa Travers-Mason Consultant clinical pharmacist MPH, Med, BPharm AACPA WHERE Burden of disease So what do we do stats To date: Started October 2012 770 ish reviews

More information

CKD and risk management : NICE guideline

CKD and risk management : NICE guideline CKD and risk management : NICE guideline 2008-2014 Shahed Ahmed Consultant Nephrologist shahed.ahmed@rlbuht.nhs.uk Key points : Changing parameters of CKD and NICE guidance CKD and age related change of

More information

Medications and your Heart. RBCH Foundation Trust

Medications and your Heart. RBCH Foundation Trust Medications and your Heart RBCH Foundation Trust Today I will try and cover Confusing cocktail of drugs? What are they for? How do I take them? What if I forget to take them? What are common side effects?

More information

Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)

Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) The purpose of this special edition of the PACE Bulletin is to summarize the

More information

Initial assessment of patient with AF in primary care DR BRUCE TAYLOR GPwSI Cardiology SCN Merseyside and Cheshire Clinical Lead Primary care

Initial assessment of patient with AF in primary care DR BRUCE TAYLOR GPwSI Cardiology SCN Merseyside and Cheshire Clinical Lead Primary care Initial assessment of patient with AF in primary care DR BRUCE TAYLOR GPwSI Cardiology SCN Merseyside and Cheshire Clinical Lead Primary care 11 th and 25 th September 2014 3 KEY OBJECTIVES OF TALK 1.

More information

Cardiovascular Pharmacotherapy

Cardiovascular Pharmacotherapy Cardiovascular Pharmacotherapy Overview Mechanism of cardiovascular drugs Indications and clinical use in cardiology Renin-Angiotensin Inhibitors: Angiotensin-Converting Enzyme Inhibitors, Angiotensin

More information

Arrhythmia Care in the DGH What Still Needs to be Done? Dr. Sundeep Puri Consultant Cardiologist

Arrhythmia Care in the DGH What Still Needs to be Done? Dr. Sundeep Puri Consultant Cardiologist Arrhythmia Care in the DGH What Still Needs to be Done? Dr. Sundeep Puri Consultant Cardiologist LOTS!!! This presentation confines itself to the situation in the North West. The views expressed are my

More information

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018 Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management

More information

Adherence to health behaviour advice in heart failure

Adherence to health behaviour advice in heart failure Adherence to health behaviour advice in heart failure Prof. Nana Pogosova National Research Center for Preventive Medicine Moscow, Russian Federation Heart Failure (HF) As the final point for many cardiac

More information

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic

More information

Know the Quality of our Care at Every Step. Kansas City ACS Summit BI-State Cardiovascular Education Consortium

Know the Quality of our Care at Every Step. Kansas City ACS Summit BI-State Cardiovascular Education Consortium Know the Quality of our Care at Every Step Kansas City ACS Summit BI-State Cardiovascular Education Consortium Welcome to the Kansas City ACS Summit Objectives: Follow the flow and care of an ACS patient

More information

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer

More information

Pharmaceutical Care of People with Atrial Fibrillation. Course information

Pharmaceutical Care of People with Atrial Fibrillation. Course information Pharmaceutical Care of People with Atrial Fibrillation Course information Pharmaceutical Care of People with Atrial Fibrillation Course information page 3 Introduction 5 Teaching plan 6 Needs Assessment

More information

Coronary Heart Disease. Iqbal Malik

Coronary Heart Disease. Iqbal Malik Coronary Heart Disease Iqbal Malik Pathophysiology IHD Case chest pain Question -interactive What is the result of the exercise test? 1. negative 2. positive 3. equivocal 4. other Q2 answer STEMI! What

More information

E-portfolio guide. This guide will take you through, step by step, the type of information we expect you to record at each stage of your cycle.

E-portfolio guide. This guide will take you through, step by step, the type of information we expect you to record at each stage of your cycle. E-portfolio guide The e-portfolio is designed to help you become a reflective learner and to emphasise the knowledge you are picking up on a daily basis. This guide will take you through, step by step,

More information

Helen Williams Consultant Pharmacist for CV Disease - South London

Helen Williams Consultant Pharmacist for CV Disease - South London Helen Williams Consultant Pharmacist for CV Disease - South London CVD remains the leading cause of death in the UK Accounts for a third of all deaths 46,000 deaths in people < 75 years (70% of these

More information

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority

More information

ACE. Inhibitors. Quiz feedback

ACE. Inhibitors. Quiz feedback ACE Inhibitors Quiz feedback bpac nz better medicin e bpac nz Quiz feedback, ACE inhibitors, 2006 Best Practice Advocacy Centre ACE inhibitors quiz feedback bpac nz Development Team: Rachael Clarke Sonia

More information